Sodium zirconium cyclosilicate (SZC), a newly-developed selective potassium binder, has been clinically available to treat hyperkalemia. SZC might be a promising option to manage hyperkalemia, particularly in patients with heart failure, who often require potassium-sparing medications. However, the optimal initial dose of SZC therapy at a loading dose (30 g per day for the initial 2 days) versus a maintenance dose (5 g per day) remains unknown.

中文翻译：

---

使用环硅酸锆钠治疗慢性心力衰竭的高钾血症

环硅酸锆钠 (SZC) 是一种新开发的选择性钾结合剂，已在临床上用于治疗高钾血症。SZC 可能是管理高钾血症的一个有前景的选择，特别是对于经常需要保钾药物的心力衰竭患者。然而，负荷剂量（最初 2 天每天 30 g）与维持剂量（每天 5 g）的 SZC 治疗的最佳初始剂量仍然未知。